Takuro Yukawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takuro Yukawa has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Katsuhiko Shimizu
Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
8 shared publications - Ai Maeda
Department of General Thoracic Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki Okayama, 701-0192, Japan
7 shared publications - Masao Nakata
Department of General Thoracic Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki Okayama, 701-0192, Japan
7 shared publications - Riki Okita
Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan
4 shared publications - Shinsuke Saisho
Department of General Thoracic Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki Okayama, 701-0192, Japan
4 shared publications - Yuji Hirami
Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama, 701-0192, Japan
4 shared publications
Latest Publications
- Open Access
- 29 June 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 1-4
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy. An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three more times. Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib therapy.
- 29 June 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 1-4
Open AccessPneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
Pneumatosis intestinalis (PI) is defined as the presence of gas in the bowel wall and is a relatively rare finding. PI has been associated with various pathological conditions and medications. Although several chemotherapeutic agents and molecular targeted therapy agents are reported to be associated with PI, there have been few reports describing the association between the anti-epidermal growth factor receptor agent gefitinib, a tyrosine kinase inhibitor (TKI), and PI. The present report describes a case of PI secondary to gefitinib therapy. An 80-year-old woman who had been diagnosed with recurrent lung adenocarcinoma presented with remarkable appetite loss, abdominal distension, and constipation after starting gefitinib therapy. A computed tomography (CT) scan of the abdomen revealed PI extending from the small intestine to the rectum. The patient was managed conservatively, and gefitinib therapy was discontinued. Subsequently, the symptoms improved and a follow-up abdominal X-ray showed a reduction in intramural air. After gefitinib was restarted, PI occurred three more times. Although PI is extremely rare, physicians should be aware of the risk of PI in patients undergoing gefitinib therapy.
- Open Access
- 1 January 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 21
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued in terms of its efficacy, and the search for treatment prediction biomarkers is imperative for the further identification of treatable subgroups. Therefore, we investigated the significance of cyclooxygenase-2 (Cox-2) expression and the applicability of a Cox-2 inhibitor in patients who had received adjuvant chemotherapy. We conducted a retrospective review of data from 97 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). The criteria for regimen selection were based on a discussion among the cancer board and enrollment in a clinical trial. Immunohistochemical staining (IHC) for Cox-2 was performed, and the correlation between Cox-2 expression and disease-free survival (DFS) was evaluated. IHC showed that 56 cases (57.7%) were positive for Cox-2. The rate of Cox-2 expression was similar for the PB and OT groups. Among the patients who received PB, the DFS of the patients with Cox-2 expression was significantly poorer than that of the patients without Cox-2 expression (P = 0.017), but there was no significant difference among the patients who received OT (P = 0.617). In a multivariate analysis, Cox-2 expression and lymph node metastasis were independent predictors of DFS among patients who received PB. Cox-2 expression was a powerful predictor of DFS among patients who received PB as an adjuvant chemotherapy. Further study investigating the use of a Cox-2 inhibitor for adjuvant chemotherapy is needed.
- 1 January 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 21
Open AccessCyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued in terms of its efficacy, and the search for treatment prediction biomarkers is imperative for the further identification of treatable subgroups. Therefore, we investigated the significance of cyclooxygenase-2 (Cox-2) expression and the applicability of a Cox-2 inhibitor in patients who had received adjuvant chemotherapy. We conducted a retrospective review of data from 97 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). The criteria for regimen selection were based on a discussion among the cancer board and enrollment in a clinical trial. Immunohistochemical staining (IHC) for Cox-2 was performed, and the correlation between Cox-2 expression and disease-free survival (DFS) was evaluated. IHC showed that 56 cases (57.7%) were positive for Cox-2. The rate of Cox-2 expression was similar for the PB and OT groups. Among the patients who received PB, the DFS of the patients with Cox-2 expression was significantly poorer than that of the patients without Cox-2 expression (P = 0.017), but there was no significant difference among the patients who received OT (P = 0.617). In a multivariate analysis, Cox-2 expression and lymph node metastasis were independent predictors of DFS among patients who received PB. Cox-2 expression was a powerful predictor of DFS among patients who received PB as an adjuvant chemotherapy. Further study investigating the use of a Cox-2 inhibitor for adjuvant chemotherapy is needed.
- Open Access
- 1 January 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 343
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma
The maximal standardized uptake value (SUVmax) on fluorodeoxyglucose-positron emission tomography (FDG-PET) for primary tumors is correlated with clinicopathological and prognostic factors in patients with non-small cell lung cancer. However, previous investigations have discussed the role of SUVmax without distinguishing among the histological subtypes of lung cancer. Herein, we investigated the correlations among the SUVmax on FDG-PET, clinicopathological or prognostic factors, and the expression of tumor angiogenic biomarkers according to histological subtypes. We conducted a retrospective review of data from 52 patients with invasive adenocarcinoma (ADC) and 32 patients with squamous cell carcinoma (SQC) measuring less than 3 cm in diameter. Immunohistochemical staining for cyclooxygenase-2 (Cox-2), Ki-67, and vascular endothelial growth factor, which might influence cancer progression, was performed and the correlations between the expressions of these biomarkers and the SUVmax were evaluated. Among ADC patients, a statistically significant correlation was observed between the SUVmax and the major clinicopathological factors; among SQC patients, however, no statistically significant association was observed. The disease-free survival (DFS) period of the ADC patients with a high SUVmax was significantly poorer than that of the patients with a low SUVmax, but the DFS of the SQC patients with a high SUVmax was not significantly poorer. In a multivariate analysis, the pathological stage and the SUVmax were independent prognostic factors of the DFS among the ADC patients. Among the SQC patients, however, only Cox-2 expression was an independent prognostic factor of DFS. Some clear differences in prognostic values of the SUVmax on FDG-PET and Cox-2 expression exist between patients with ADC and those with SQC. Based on these relationships between the SUVmax and clinicopathological or biological factors that influence cancer progression, the importance of the SUVmax appears to be quite different for patients with ADC and those with SQC.
- 1 January 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 343
Open AccessDifference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma
The maximal standardized uptake value (SUVmax) on fluorodeoxyglucose-positron emission tomography (FDG-PET) for primary tumors is correlated with clinicopathological and prognostic factors in patients with non-small cell lung cancer. However, previous investigations have discussed the role of SUVmax without distinguishing among the histological subtypes of lung cancer. Herein, we investigated the correlations among the SUVmax on FDG-PET, clinicopathological or prognostic factors, and the expression of tumor angiogenic biomarkers according to histological subtypes. We conducted a retrospective review of data from 52 patients with invasive adenocarcinoma (ADC) and 32 patients with squamous cell carcinoma (SQC) measuring less than 3 cm in diameter. Immunohistochemical staining for cyclooxygenase-2 (Cox-2), Ki-67, and vascular endothelial growth factor, which might influence cancer progression, was performed and the correlations between the expressions of these biomarkers and the SUVmax were evaluated. Among ADC patients, a statistically significant correlation was observed between the SUVmax and the major clinicopathological factors; among SQC patients, however, no statistically significant association was observed. The disease-free survival (DFS) period of the ADC patients with a high SUVmax was significantly poorer than that of the patients with a low SUVmax, but the DFS of the SQC patients with a high SUVmax was not significantly poorer. In a multivariate analysis, the pathological stage and the SUVmax were independent prognostic factors of the DFS among the ADC patients. Among the SQC patients, however, only Cox-2 expression was an independent prognostic factor of DFS. Some clear differences in prognostic values of the SUVmax on FDG-PET and Cox-2 expression exist between patients with ADC and those with SQC. Based on these relationships between the SUVmax and clinicopathological or biological factors that influence cancer progression, the importance of the SUVmax appears to be quite different for patients with ADC and those with SQC.
- Open Access
- 23 March 2013
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 62 (4) , 252-254
A case report of intrapulmonary schwannoma
A 38-year-old man without any symptoms was admitted to our institution because of an abnormal shadow found incidentally on a chest X-ray. Chest computed tomography showed a round mass in the lingular segment of the left upper lobe. Lingular segmentectomy was performed, and the histopathological diagnosis was intrapulmonary schwannoma. Immunohistochemical staining revealed a positive result for S-100 protein and negative results for CD34 and desmin. We report this case of intrapulmonary schwannoma, which is extremely rare.
- 23 March 2013
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 62 (4) , 252-254
Open AccessA case report of intrapulmonary schwannoma
A 38-year-old man without any symptoms was admitted to our institution because of an abnormal shadow found incidentally on a chest X-ray. Chest computed tomography showed a round mass in the lingular segment of the left upper lobe. Lingular segmentectomy was performed, and the histopathological diagnosis was intrapulmonary schwannoma. Immunohistochemical staining revealed a positive result for S-100 protein and negative results for CD34 and desmin. We report this case of intrapulmonary schwannoma, which is extremely rare.
- Open Access
- 11 July 2012
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 10 (1) , 141
Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients
The purpose of this study is to clarify the correlations between the expression of membrane-bound estrogen receptor-α (mERα) and epidermal growth factor receptor (EGFR) mutation and clinicopathological factors, especially in relation to the prognosis, in patients with lung adenocarcinoma.
- 11 July 2012
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 10 (1) , 141
Open AccessMembrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients
The purpose of this study is to clarify the correlations between the expression of membrane-bound estrogen receptor-α (mERα) and epidermal growth factor receptor (EGFR) mutation and clinicopathological factors, especially in relation to the prognosis, in patients with lung adenocarcinoma.
- 1 October 2010
- Vol. 16 (5) , 326-30
Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor.
In this study, we retrospectively evaluate the safety and efficacy of induction chemoradiation using cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor (SST). We reviewed the records of four patients with solitary, previously untreated T3-4, N0-1 superior sulcus nonsmall cell lung cancers. Patients received two cycles of chemotherapy, cisplatin and irinotecan, every 4 weeks. Radiotherapy directed at the tumor was administered with a split schedule at the total dose of 40 Gy in 20 fractions. Thoracotomy was performed 4 weeks after completion of the chemoradiation. The toxicities of chemoradiation were mainly hematologic and were well-tolerated. Complete resection could be performed in all cases, and there was no postoperative mortality. At present, all the patients remain alive, and one has a local recurrence. This trimodality approach is a safe and effective approach for the local control of SST. Further studies are necessary to confirm the results.
- 1 October 2010
- Vol. 16 (5) , 326-30
Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor.
In this study, we retrospectively evaluate the safety and efficacy of induction chemoradiation using cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor (SST). We reviewed the records of four patients with solitary, previously untreated T3-4, N0-1 superior sulcus nonsmall cell lung cancers. Patients received two cycles of chemotherapy, cisplatin and irinotecan, every 4 weeks. Radiotherapy directed at the tumor was administered with a split schedule at the total dose of 40 Gy in 20 fractions. Thoracotomy was performed 4 weeks after completion of the chemoradiation. The toxicities of chemoradiation were mainly hematologic and were well-tolerated. Complete resection could be performed in all cases, and there was no postoperative mortality. At present, all the patients remain alive, and one has a local recurrence. This trimodality approach is a safe and effective approach for the local control of SST. Further studies are necessary to confirm the results.
- 1 April 2010
- Vol. 16 (2) , 122-4
Pulmonary apical mass, the so-called pulmonary apical cap, in a 43-year-old woman.
A 43-year-old woman had a pulmonary tumor detected by a computed tomographic (CT) scan during follow-up for breast cancer 15 years previously. The tumor showed a solid mass measuring 42 × 32 × 12 mm in extensive contact with the pleura of the apex of the left upper lobe. The edge of the tumor was relatively well-defined with an irregular shape, and a bubblelike area was seen within it. The longitudinal slice high-resolution CT findings showed a flat and thick mass, and its inferior border was distinct and horizontal. The pathological findings by a thoracoscopic lung biopsy showed a localized pulmonary fibrosis of the apex, a so-called pulmonary apical cap (PAC). With the recent advances in CT scan technology, the detection of PACs is very likely to increase, and they must be differentiated from superior sulcus tumors.
- 1 April 2010
- Vol. 16 (2) , 122-4
Pulmonary apical mass, the so-called pulmonary apical cap, in a 43-year-old woman.
A 43-year-old woman had a pulmonary tumor detected by a computed tomographic (CT) scan during follow-up for breast cancer 15 years previously. The tumor showed a solid mass measuring 42 × 32 × 12 mm in extensive contact with the pleura of the apex of the left upper lobe. The edge of the tumor was relatively well-defined with an irregular shape, and a bubblelike area was seen within it. The longitudinal slice high-resolution CT findings showed a flat and thick mass, and its inferior border was distinct and horizontal. The pathological findings by a thoracoscopic lung biopsy showed a localized pulmonary fibrosis of the apex, a so-called pulmonary apical cap (PAC). With the recent advances in CT scan technology, the detection of PACs is very likely to increase, and they must be differentiated from superior sulcus tumors.
- 1 January 2010
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 24 (2) , 242-246
A case report of solitary plasmacytoma of the sternum
- 1 January 2010
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 24 (2) , 242-246
A case report of solitary plasmacytoma of the sternum